Cargando…

Influence of Intratumor Heterogeneity on the Predictivity of MGMT Gene Promoter Methylation Status in Glioblastoma

Glioblastoma is the most aggressive tumor of the central nervous system. Prognosis is poor, even in the presence of a methylated state of MGMT gene promoter, which represents the biomarker with the highest prognostic/predictive value for the standard treatment of patients. Among patients with a meth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brigliadori, Giovanni, Goffredo, Giulia, Bartolini, Daniela, Tosatto, Luigino, Gurrieri, Lorena, Mercatali, Laura, Ibrahim, Toni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606920/ https://www.ncbi.nlm.nih.gov/pubmed/33194592 http://dx.doi.org/10.3389/fonc.2020.533000

Ejemplares similares

MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas
por: Fuster-Garcia, Elies, et al.
Publicado: (2020)

Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series
por: Gurrieri, Lorena, et al.
Publicado: (2023)

Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
por: Incekara, Fatih, et al.
Publicado: (2020)

Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
por: Zappe, Katja, et al.
Publicado: (2023)

The Intratumoral Heterogeneity Reflects the Intertumoral Subtypes of Glioblastoma Multiforme: A Regional Immunohistochemistry Analysis
por: Bergmann, Natalie, et al.
Publicado: (2020)

The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma
por: Incekara, Fatih, et al.
Publicado: (2020)

MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?
por: Hau, Peter, et al.
Publicado: (2007)

Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
por: Thon, Niklas, et al.
Publicado: (2013)

MGMT promoter methylation in Peruvian patients with glioblastoma
por: Belmar-Lopez, Carolina, et al.
Publicado: (2018)

Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification
por: Wenger, Anna, et al.
Publicado: (2019)

Measuring Intratumoral Heterogeneity of Immune Repertoires
por: Yuzhakova, Diana Vladimirovna, et al.
Publicado: (2020)

Intratumor Heterogeneity in Early Lung Adenocarcinoma
por: Senosain, Maria-Fernanda, et al.
Publicado: (2020)

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
por: Marchi, Francesco, et al.
Publicado: (2020)

An evaluation of MGMT promoter methylation within the methylation subclasses of glioblastoma
por: Alnahhas, Iyad, et al.
Publicado: (2020)

Unifying models of glioblastoma’s intratumoral heterogeneity
por: Lam, K H Brian, et al.
Publicado: (2020)

MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas
por: Korfiatis, Panagiotis, et al.
Publicado: (2016)

Tim-3 Expression and MGMT Methylation Status Association With Survival in Glioblastoma
por: Zhang, Ji, et al.
Publicado: (2020)

Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma
por: Nguyen, Ngan, et al.
Publicado: (2021)

Peritumoral ADC Values Correlate with the MGMT Methylation Status in Patients with Glioblastoma
por: Ladenhauf, Valentin Karl, et al.
Publicado: (2023)

Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastoma
por: Yoshioka, Masaki, et al.
Publicado: (2018)

Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma
por: Uno, Miyuki, et al.
Publicado: (2011)

Quantitative Analysis of the MGMT Methylation Status of Glioblastomas in Light of the 2021 WHO Classification
por: Häni, Levin, et al.
Publicado: (2022)

Evaluation of the Impact of Intratumoral Heterogeneity of Esophageal Cancer on Pathological Diagnosis and P16 Methylation and the Representativity of Endoscopic Biopsy
por: Qin, Yu, et al.
Publicado: (2021)

Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation
por: Kim, Se-Hyuk, et al.
Publicado: (2018)

Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma
por: Sasaki, Takahiro, et al.
Publicado: (2019)

The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma
por: Hsu, Chih-Yi, et al.
Publicado: (2017)

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
por: Melguizo, Consolación, et al.
Publicado: (2012)

Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region
por: Kanemoto, Manabu, et al.
Publicado: (2014)

Prognostic Role of Methylation Status of the MGMT Promoter Determined Quantitatively by Pyrosequencing in Glioblastoma Patients
por: Kim, Dae Cheol, et al.
Publicado: (2016)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()
por: Myung, Jae Kyung, et al.
Publicado: (2014)

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2020)

The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status
por: Chen, Wei-jun, et al.
Publicado: (2020)

A Time-Based and Intratumoral Proteomic Assessment of a Recurrent Glioblastoma Multiforme
por: de Aquino, Priscila F., et al.
Publicado: (2016)

Intratumoral Heterogeneity, Its Contribution to Therapy Resistance and Methodological Caveats to Assessment
por: Renovanz, Mirjam, et al.
Publicado: (2014)

Intratumor Heterogeneity of MIF Expression Correlates With Extramedullary Involvement of Multiple Myeloma
por: Xu, Juan, et al.
Publicado: (2021)

Appraisal of re-irradiation for the recurrent glioblastoma in the era of MGMT promotor methylation
por: Kim, Il Han
Publicado: (2019)

Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
por: Tunthanathip, Thara, et al.
Publicado: (2021)

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
por: Jue, Toni Rose, et al.
Publicado: (2017)

The Effects of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer—The Impact in Intratumoral Heterogeneity
por: Bettoni, Fabiana, et al.
Publicado: (2019)

Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients
por: Lin, Zhen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r82s31sspj33fu68oi9ucb4p3d